Quick Answer
Arbutus Biopharma Corp reported R&D Expense of $25.24 million for fiscal year 2025.
Arbutus Biopharma Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $25.24M | -53.3% |
| 2024 | $54.04M | -26.7% |
| 2023 | $73.70M | -12.7% |
| 2022 | $84.41M | +28.9% |
| 2021 | $65.50M | +32.8% |
| 2020 | $49.34M | -14.3% |
| 2019 | $57.60M | -0.6% |
| 2018 | $57.93M | -7.6% |
| 2017 | $62.68M | +2.3% |
| 2016 | $61.25M | +18.9% |
| 2015 | $51.51M | +33.0% |
| 2014 | $38.71M | +80.4% |
| 2013 | $21.46M | +18.9% |
| 2012 | $18.04M | -10.4% |
| 2011 | $20.13M | -9.0% |
| 2010 | $22.13M | +24.6% |
| 2009 | $17.76M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.78M | -59.5% | +5.1% |
| June 30, 2025 | $5.50M | -64.6% | -38.6% |
| March 31, 2025 | $8.96M | -41.8% | -37.2% |
| September 30, 2024 | $14.27M | -29.2% | -8.2% |
| June 30, 2024 | $15.55M | -12.1% | +1.0% |
| March 31, 2024 | $15.40M | -15.7% | -23.6% |
| September 30, 2023 | $20.17M | +0.6% | +14.0% |
| June 30, 2023 | $17.69M | -22.9% | -3.2% |
- Arbutus Biopharma Corp showed a decrease of -53.3% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Arbutus Biopharma Corp’s r&d expense has grown by 42.1% (from $17.76 million to $25.24 million).
- The most recent figure is from Arbutus Biopharma Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: